WO2022255583A1 - 호모해링토닌을 유효성분으로 함유하는 근육질환 예방 또는 치료용 조성물 - Google Patents
호모해링토닌을 유효성분으로 함유하는 근육질환 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2022255583A1 WO2022255583A1 PCT/KR2022/000910 KR2022000910W WO2022255583A1 WO 2022255583 A1 WO2022255583 A1 WO 2022255583A1 KR 2022000910 W KR2022000910 W KR 2022000910W WO 2022255583 A1 WO2022255583 A1 WO 2022255583A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- homoharringtonine
- muscle
- preventing
- group
- active ingredient
- Prior art date
Links
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 title claims abstract description 49
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 title claims abstract description 49
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 title claims abstract description 47
- 208000029578 Muscle disease Diseases 0.000 title claims abstract description 20
- 239000004480 active ingredient Substances 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title abstract description 9
- 210000003205 muscle Anatomy 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 235000013402 health food Nutrition 0.000 claims abstract description 10
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 10
- 230000037396 body weight Effects 0.000 claims description 22
- 208000001076 sarcopenia Diseases 0.000 claims description 12
- 201000006938 muscular dystrophy Diseases 0.000 claims description 11
- 206010028372 Muscular weakness Diseases 0.000 claims description 8
- 201000002481 Myositis Diseases 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 206010021118 Hypotonia Diseases 0.000 claims description 4
- 208000007379 Muscle Hypotonia Diseases 0.000 claims description 4
- 208000010428 Muscle Weakness Diseases 0.000 claims description 4
- 206010061533 Myotonia Diseases 0.000 claims description 4
- 230000036473 myasthenia Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 210000002027 skeletal muscle Anatomy 0.000 abstract description 16
- 210000003141 lower extremity Anatomy 0.000 abstract description 10
- 230000032683 aging Effects 0.000 abstract description 9
- 238000010171 animal model Methods 0.000 abstract description 8
- 230000009467 reduction Effects 0.000 abstract description 3
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- 230000003387 muscular Effects 0.000 abstract 2
- 230000001629 suppression Effects 0.000 abstract 1
- 235000009200 high fat diet Nutrition 0.000 description 22
- 230000037406 food intake Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 235000012631 food intake Nutrition 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 230000001186 cumulative effect Effects 0.000 description 7
- 235000021590 normal diet Nutrition 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- -1 for example Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241001423670 Cephalotaxus hainanensis Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HAVJATCHLFRDHY-UHFFFAOYSA-N Harringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HAVJATCHLFRDHY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000013237 diet-induced animal model Methods 0.000 description 1
- 238000011643 diet-induced obesity animal model Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- HAVJATCHLFRDHY-JZTSUELASA-N harringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@](O)(CCC(C)(C)O)CC(=O)OC)[C@@H]4C2=CC2=C1OCO2 HAVJATCHLFRDHY-JZTSUELASA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
Definitions
- the present invention relates to a composition for preventing or treating muscle diseases containing homoharringtonine as an active ingredient.
- Aging of skeletal muscle is presented as an important cause of not only metabolic diseases such as diabetes, but also physical disorders such as fractures and falls, and is known to be an important cause of lowering the quality of life in the elderly. Recently, it has been reported that the aging of skeletal muscle is related to the aging of other tissues and the lifespan of the living body. have.
- An object of the present invention is to provide a composition containing homoharringtonine as an active ingredient as a pharmaceutical composition and health food for preventing or treating sarcopenia by inhibiting the decrease in the amount and strength of skeletal muscle.
- the present invention provides a pharmaceutical composition for preventing or treating muscle diseases containing homoharringtonine as an active ingredient.
- the present invention provides a health food for preventing or improving muscle diseases containing homoharringtonine as an active ingredient.
- a composition containing harringtonine as an active ingredient may be provided as a pharmaceutical composition and health food for preventing or treating muscle diseases caused by muscle or muscle strength reduction.
- Figure 1 is a result of confirming the body weight, food intake and gastrocnemius weight in high-fat diet-induced obese animals
- Figure 1A is a normal diet group (Ch) and high-fat diet intake phosphate buffered saline administration group (HF-PBS; high-fat diet intake control group ), the result of confirming the weight change over time in the high-fat diet homoharringtonine administration group (HF-HHT; high-fat diet intake drug group)
- Figures 1B and 1C confirm the cumulative food intake and weight of the gastrocnemius, respectively
- the gastrocnemius weight was corrected as body weight (expressed as % of body weight).
- Body weight increased significantly in the high-fat diet group compared to the normal diet group.
- Figure 2 is the result of confirming the weight, food intake, muscle strength measurement and muscle weight of aged mice
- Figure 2A is the result of confirming the change in body weight during the administration of homoharringtonin in 18-month-old aged mice
- Figure 2B shows the cumulative food intake
- Figure 2C is a result of measuring muscle strength through an upside-down hanging experiment after 14 weeks of administration of homoharringtonine
- Figure 2D is a result of measuring the weight of the gastrocnemius muscle after sacrifice of mice
- Figure 2E is a result of homoharringtonine administration 6 This is the result of confirming the change in body weight after 6 months
- FIG. 2F is the result of confirming the grip strength 6 months after administration of homoharringtonine.
- Figure 3 is a result of confirming the weight, food intake, weight of the gastrocnemius and tibialis anterior muscle in the lower extremity fixed muscular atrophy animal model
- Figure 3A is the result of confirming the weight change in the lower extremity fixed muscular atrophy animal model
- Figure 3B shows the cumulative intake 3C is a result of confirming the weight change of the gastrocnemius muscle
- FIG. 3D is a result of confirming the weight change of the tibialis anterior muscle.
- the weight of the fixed left leg was significantly lower than that of the right leg in the control group, but there was no significant decrease in the weight of the skeletal muscle due to fixation in the experimental group administered with homoharringtonine.
- skeletal muscle weight decreased by fixation in the phosphate-buffered saline-treated group, but there was no difference in the homoharringtonine-injected group.
- Homoharringtonine is a single component of natural product isolated from Cephalotaxus hainanensis and is used as a treatment for chronic myeloid leukemia.
- the inventors of the present invention completed the present invention by confirming the effect of homoharringtonine on improving the amount and strength of skeletal muscle in obese and aging mice and animal models of lower limb immobilized muscular atrophy.
- the present invention can provide a pharmaceutical composition for preventing or treating muscle diseases containing homoharringtonine as an active ingredient.
- the muscle disease is sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy ( muscular dystrophy), amyotrophic lateral sclerosis, and inflammatory myopathy.
- the pharmaceutical composition may contain 0.01 to 10 parts by weight of homoharringtonine based on 100 parts by weight of the total pharmaceutical composition.
- the homoharringtonine may inhibit muscle loss and increase muscle strength without changing body weight.
- the pharmaceutical composition for preventing or treating muscle diseases containing homoharringtonine as an active ingredient is injected, granules, powders, tablets, pills, capsules, suppositories, gels, or suspensions according to conventional methods. Any one formulation selected from the group consisting of agents, emulsions, drops, and liquids may be used.
- the pharmaceutical composition is a suitable carrier, excipient, disintegrant, sweetener, coating agent, swelling agent, lubricant, flavoring agent, antioxidant, buffer, bacteriostatic agent, diluent commonly used in the manufacture of pharmaceutical compositions , It may further include one or more additives selected from the group consisting of dispersants, surfactants, binders, and lubricants.
- carriers, excipients and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil may be used, and solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules.
- solid preparations may be prepared by mixing at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the composition.
- excipients for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc.
- lubricants such as magnesium stearate and talc may also be used.
- Liquid preparations for oral administration include suspensions, solutions for oral use, emulsions, syrups, and the like, and various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included in addition to commonly used simple diluents such as water and liquid paraffin.
- Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
- As a base material of the suppository witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.
- the pharmaceutical composition is administered in a conventional manner through intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, intranasal, inhalational, topical, rectal, oral, intraocular or intradermal routes.
- the preferred dosage of homoharringtonine may vary depending on the condition and body weight of the subject, the type and severity of the disease, the type of drug, the route and duration of administration, and may be appropriately selected by a person skilled in the art. According to one embodiment of the present invention, but not limited thereto, the daily dosage may be 0.01 to 200 mg/kg, specifically 0.1 to 200 mg/kg, and more specifically 0.1 to 100 mg/kg. Administration may be administered once a day or divided into several administrations, and the scope of the present invention is not limited thereby.
- the 'subject' may be a mammal including a human, but is not limited to these examples.
- the present invention can provide a health food for preventing or improving muscle diseases containing homoharringtonine as an active ingredient.
- the muscle disease is sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy ( muscular dystrophy), amyotrophic lateral sclerosis, and inflammatory myopathy.
- the health food may be used together with other foods or food additives in addition to the homoharringtonine, and may be appropriately used according to a conventional method.
- the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use thereof, for example, prevention, health or therapeutic treatment.
- the effective dose of the compound contained in the health food may be used according to the effective dose of the therapeutic agent, but may be less than the above range in the case of long-term intake for the purpose of health and hygiene or health control. Since there is no problem in terms of safety, it is certain that the components can be used in an amount greater than the above range.
- mice were placed on the wire net for hanging one by one, and the wire was turned over at the same time as the start, and seconds were measured until all four legs fell off.
- a wire mesh with a size of 43 ⁇ 34 cm was used, and the spacing of each wire was 1.2 cm.
- the height of the wire mesh was maintained at 1.2 m from the floor, and a litter was placed on the floor to minimize impact after a fall.
- the grip strength of each mouse was measured using a grip strength meter (Bioseb, Vitrolles, France). The value was set to 0 for each measurement to detect an appropriate value, and the maximum grip strength value was measured at least three times by having the mouse hold the meter with both forelimbs and pulling the tail with the mouse positioned so that the body and the ground were level.
- the high-fat diet-induced obesity animal model divided 8-week-old C57BL/6 male mice into a normal diet intake group and a high-fat diet intake group. , R&D systems, Minneapolis, MN, USA), and the normal diet group consumed a chow diet (Envigo, Indianapolis, IN, USA).
- the mice were reared in an environment controlled by a room temperature of 22 ⁇ 2 °C and a 12-hour light/dark cycle until the end of the experiment, and their body weight and food intake were manually measured at weekly intervals.
- mice were randomly divided into a control group and an experimental group after 6 weeks of ingestion of the high-fat diet, and phosphate-buffered saline was administered to the control group and homoharringtonine was intraperitoneally administered to the experimental group.
- Homoharringtonine was dissolved at 10 mM in dimethyl sulfoxide in 10 mg of TOCRIS, UK, and 0.545 ⁇ g/g body weight per animal was intraperitoneally administered three times a week for 8 weeks.
- the same dose of phosphate buffered saline was administered intraperitoneally to the normal group.
- the body weight increased significantly after 3 weeks of intake in the high-fat diet intake group compared to the normal diet intake group.
- Administration of homoharringtonine was started 6 weeks after ingestion of the high-fat diet.
- the experimental group to which homoharringtonine was administered showed a significantly lower weight gain from 2 weeks after the injection of the drug, but the intake of the high-fat diet There was no significant difference between the control group and the experimental group.
- the gastrocnemius weight of the lower extremity was significantly lower in the high-fat diet intake group than in the normal diet intake group, but significantly higher in the high-fat diet intake experimental group than in the high-fat diet intake control group.
- mice After adapting to the breeding environment for one week, aging mice were randomly divided into control and experimental groups, and phosphate-buffered saline was administered to the control group and homoharringtonine (0.545 ⁇ g/g body weight) to the experimental group intraperitoneally three times a week for more than 4 months. did
- the body weight of aged mice tended to decrease after 7 weeks of administration in the experimental group administered with homoharringtonine, but there was no statistically significant difference compared to the control group administered with phosphate buffered saline. Cumulative food intake was also not significantly different between the two groups.
- the lower extremity immobilization animal model is an animal model that induces muscular atrophy by reducing the weight load, and Caron et al. (A novel hindlimb immoilization procedure for studying skeletal muscle atrophy and recovery in mouse. J Appl Physiol. 2009 Jun;106(6): 2049-59.) using a skin stapler (Manipler ® AZ, Utsunomiya, Tochigi, Japan). The unfixed right side was used as a control.
- Phosphate-buffered saline was administered intraperitoneally to the control group and homoharringtonine (0.545 ⁇ g/g body weight) to the experimental group three times a week from 1 week before immobilization to 3 weeks during the immobilization period for a total of 4 weeks.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
- 호모해링토닌을 유효성분으로 함유하는 근육질환 예방 또는 치료용 약학조성물.
- 청구항 1에 있어서, 상기 근육질환은 근감소증(sarcopenia), 근위축증(muscular atrophy), 근무력증(myasthenia), 근이영양증(muscular dystrophy), 근육긴장증(myotonia), 근긴장 저하(hypotonia), 근력 약화(muscular weakness), 근육퇴행위축(muscular dystrophy), 근위축성 측삭경화증(amyotrophic lateral sclerosis) 및 염증성 근육병(inflammatory myopathy)으로 이루어진 군에서 하나 이상 선택되는 것을 특징으로 하는 근육질환 예방 또는 치료용 약학조성물.
- 청구항 1에 있어서, 상기 약학조성물은 약학조성물 총 100 중량부에 대하여, 호모해링토닌 0.01 내지 10 중량부를 포함하는 것을 특징으로 하는 근육질환 예방 또는 치료용 약학조성물.
- 청구항 1에 있어서, 상기 호모해링토닌은 체중 변화 없이 근육 감소를 저해하고 근력을 증가시키는 것을 특징으로 하는 근육질환 예방 또는 치료용 약학조성물.
- 호모해링토닌을 유효성분으로 함유하는 근육질환 예방 또는 개선용 건강식품.
- 청구항 5에 있어서, 상기 근육질환은 근감소증(sarcopenia), 근위축증(muscular atrophy), 근무력증(myasthenia), 근이영양증(muscular dystrophy), 근육긴장증(myotonia), 근긴장 저하(hypotonia), 근력 약화(muscular weakness), 근육퇴행위축(muscular dystrophy), 근위축성 측삭경화증(amyotrophic lateral sclerosis) 및 염증성 근육병(inflammatory myopathy)으로 이루어진 군에서 하나 이상 선택되는 것을 특징으로 하는 근육질환 예방 또는 개선용 건강식품.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280039212.3A CN117412754A (zh) | 2021-05-31 | 2022-01-18 | 用于预防或治疗肌肉疾病的包含高三尖杉酯碱作为活性成分的组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210069690A KR102592353B1 (ko) | 2021-05-31 | 2021-05-31 | 호모해링토닌을 유효성분으로 함유하는 근육질환 예방 또는 치료용 조성물 |
KR10-2021-0069690 | 2021-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022255583A1 true WO2022255583A1 (ko) | 2022-12-08 |
Family
ID=84323337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/000910 WO2022255583A1 (ko) | 2021-05-31 | 2022-01-18 | 호모해링토닌을 유효성분으로 함유하는 근육질환 예방 또는 치료용 조성물 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102592353B1 (ko) |
CN (1) | CN117412754A (ko) |
WO (1) | WO2022255583A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101825637B1 (ko) * | 2017-04-26 | 2018-02-06 | 한국화학연구원 | 암 예방 또는 치료용 약학적 조성물 및 이의 용도 |
KR20180085124A (ko) * | 2017-01-17 | 2018-07-26 | 주식회사 파이안바이오테크놀로지 | 개비자나무 추출물 또는 이에 함유된 호모해링토닌 화합물을 포함하는 알러지 치료용 조성물 |
KR20190099613A (ko) * | 2018-02-19 | 2019-08-28 | 가천대학교 산학협력단 | 개비자나무 추출물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 자가면역질환의 예방 또는 치료용 조성물 |
KR20200072924A (ko) * | 2018-12-13 | 2020-06-23 | 영남대학교 산학협력단 | 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물 |
KR102209386B1 (ko) * | 2020-01-09 | 2021-02-01 | 영남대학교 산학협력단 | 호모해링토닌을 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101986229B1 (ko) | 2016-11-01 | 2019-06-05 | 한국식품연구원 | 천연물 추출물을 포함하는 근육질환의 개선, 예방 또는 치료용 조성물 |
-
2021
- 2021-05-31 KR KR1020210069690A patent/KR102592353B1/ko active IP Right Grant
-
2022
- 2022-01-18 CN CN202280039212.3A patent/CN117412754A/zh active Pending
- 2022-01-18 WO PCT/KR2022/000910 patent/WO2022255583A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180085124A (ko) * | 2017-01-17 | 2018-07-26 | 주식회사 파이안바이오테크놀로지 | 개비자나무 추출물 또는 이에 함유된 호모해링토닌 화합물을 포함하는 알러지 치료용 조성물 |
KR101825637B1 (ko) * | 2017-04-26 | 2018-02-06 | 한국화학연구원 | 암 예방 또는 치료용 약학적 조성물 및 이의 용도 |
KR20190099613A (ko) * | 2018-02-19 | 2019-08-28 | 가천대학교 산학협력단 | 개비자나무 추출물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 자가면역질환의 예방 또는 치료용 조성물 |
KR20200072924A (ko) * | 2018-12-13 | 2020-06-23 | 영남대학교 산학협력단 | 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물 |
KR102209386B1 (ko) * | 2020-01-09 | 2021-02-01 | 영남대학교 산학협력단 | 호모해링토닌을 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR102592353B1 (ko) | 2023-10-20 |
KR20220161676A (ko) | 2022-12-07 |
CN117412754A (zh) | 2024-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moran et al. | Gastric and nongastric mechanisms for satiety action of cholecystokinin | |
US20150265645A1 (en) | Composition For Prevention, Amelioration Or Treatment Of Metabolic Syndrome | |
EP2744493A1 (en) | Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy | |
WO2022255583A1 (ko) | 호모해링토닌을 유효성분으로 함유하는 근육질환 예방 또는 치료용 조성물 | |
US20190388448A1 (en) | Composition for cough | |
WO2012008467A1 (ja) | axial-equatorial aryl配向のfurofuran型リグナンを含有する骨形成促進用医薬組成物、その組成物を含有する医薬製剤、その組成物を含む機能性食品及び健康食品 | |
WO2012091492A2 (en) | Herbal extract, pharmaceutical composition including the same and health functional food including the same | |
WO2013100621A1 (ko) | 진저레논 에이를 포함하는 비만 예방용 식품 조성물, 비만 치료용 약학조성물 및 비만 치료용 동물용 의약품 | |
JP4510445B2 (ja) | 筋肉欠乏症を処置するのに意図した医薬を製造するためにイチョウ抽出物の使用 | |
WO2014084669A1 (ko) | 프래럽토린 a 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학적 조성물 | |
WO2021132950A1 (ko) | 아우쿠빈을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물 | |
AU2020391291B2 (en) | Combination therapy of cycloserine and lithium for the treatment of depression | |
WO2022173123A1 (ko) | 시클로엘페닐알라닐엘프롤린 디펩타이드를 포함하는 근섬유 형성의 촉진 또는 파골세포의 분화억제 기전을 통한 근감소증 또는 골다공증 치료용 조성물 | |
WO2019143219A1 (ko) | 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물 | |
AU770580B2 (en) | Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia | |
El-lethey et al. | Effects of black tea in mitigation of sodium fluoride potency to suppress motor activity and coordination in laboratory rats | |
WO2024096445A1 (ko) | 탈람파넬을 포함하는 스트레스 및 우울증 관련 질환의 개선, 예방 또는 치료용 조성물 | |
WO2020209674A1 (ko) | 비글리칸을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물 | |
WO2022092546A1 (ko) | 뼈 형성 단백질 10을 유효성분으로 함유하는 대사성질환 예방 또는 치료용 약학조성물 | |
De Lucca et al. | 21 Mycotoxins of Fusarium spp. | |
WO2022177116A1 (ko) | 형개 추출물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생, 근감소 또는 근피로의 예방, 개선 또는 치료용 조성물 | |
JP7227962B2 (ja) | 筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物 | |
Yu et al. | Erectile potentials of a new phosphodiesterase type 5 inhibitor, DA‐8159, in diet‐induced obese rats | |
WO2021225397A1 (ko) | 우울증 치료를 위한 사이클로세린 및 펜톡시필린 병용 요법 | |
WO2022045540A1 (ko) | 패 추출물 또는 그로부터 분리된 화합물을 이용한 근력 개선, 근위축 개선 또는 노화로 인한 근감소증 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22816247 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18563916 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280039212.3 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22816247 Country of ref document: EP Kind code of ref document: A1 |